Abstract Introduction Malignant mesonephric tumors are uncommon in the female genital tract, and they are usually located where embryonic remnants of Wolffian ducts are detected, such as the uterine cervix. The information about these tumors, their treatment protocol, and prognosis are scarce. Case report A 60-year-old woman with postmenopausal vaginal bleeding was initially diagnosed with endometrial carcinoma. After suspicion co-testing, the patient underwent a loop electrosurgical excision of the cervix and was eventually diagnosed with mesonephric adenocarcinoma. She was subjected to a radical hysterectomy, which revealed International Federation of Gynecology and Obstetrics (FIGO) IB1 stage, and adjuvant radiotherapy. The follow-up showed no evidence of recurrence after 60 months. Conclusion We present the case of a woman with cervical mesonephric adenocarcinoma. When compared with the literature, this case had the longest clinical follow-up without evidence of recurrence, which reinforces the concept that these tumors are associated with a favorable prognosis if managed according to the guidelines defined for the treatment of patients with cervical adenocarcinomas. Though a rare entity, it should be kept in mind as a differential diagnosis for other cervical cancers.

Non-invasive prenatal testing (NIPT) is a recent approach to prenatal aneuploidy screening. NIPT has an excellent test performance but it is not a diagnostic test, as there are known limitations associated with false positive and false negative results. When compared to standard screening, pre-test counselling is complicated by concepts such as the possibility of incidental findings. It is important for all the health professionals involved in this field to be familiarised with the state-of-the art knowledge in NIPT. The aim of this article is to review the evidence on the clinical use of NIPT for aneuploidy screening.

Pre-eclampsia is a common and potentially serious disorder of pregnancy. An antiangiogenic state appears to be central to its development. In particular, the sFlt-1/PlGF ratio increases in pre-eclampsia, leading to its potential use as a marker for prediction and diagnosis. Immunoassays for the sFlt-1/PlGF ratio are now commercially available and can assist in the diagnosis of women with a clinical suspicion of pre-eclampsia, leading to a decrease in hospital admissions. Remarkably, information is missing on the impact of its use in pregnancy outcomes